Xenon neuroprotection in experimental stroke: Interactions with hypothermia and intracerebral hemorrhage

Anesthesiology

Volumn 117, Issue 6, 2012, Pages 1262-1275

  Sheng, Siyuan P ^a   Lei, Beilei ^b   James, Michael L ^b   Lascola, Christopher D ^b   Venkatraman, Talaignair N ^b   Jung, Jin Yong ^b   Maze, Mervyn ^c   Franks, Nicholas P ^d   Pearlstein, Robert D ^b   Sheng, Huaxin ^b   Warner, David S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN; OXYGEN; SODIUM CHLORIDE; XENON;

AGITATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN WATER; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPOSURE VARIABLE; HYPOTHERMIA; MALE; MICROGLIA; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RIGHTING REFLEX; SCORING SYSTEM; SEDATION; THERAPY DELAY; THERMOREGULATION; TREATMENT DURATION; WISTAR RAT;

ANIMALS; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; HYPOTHERMIA, INDUCED; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; STROKE; XENON;

EID: 84870248092     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182746b81     Document Type: Article

References (58)

1. Bantel C, Maze M, Trapp S: Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. ANESTHESIOLOGY 2010; 112:623-30
2. Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N: Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 2001; 292:1543-6
3. Dickinson R, Peterson BK, Banks P, Simillis C, Martin JC, Valenzuela CA, Maze M, Franks NP: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: Evidence from molecular modeling and electrophysiology. ANESTHESIOLOGY 2007; 107:756-67
4. Parsons CG, Danysz W, Hesselink M, Hartmann S, Lorenz B, Wollenburg C, Quack G: Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments. Amino Acids 1998; 14:207-16
5. Nagata A, Nakao Si S, Nishizawa N, Masuzawa M, Inada T, Murao K, Miyamoto E, Shingu K: Xenon inhibits but N(2) O enhances ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices. Anesth Analg 2001; 92:362-8
6. Ma D, Williamson P, Januszewski A, Nogaro MC, Hossain M, Ong LP, Shu Y, Franks NP, Maze M: Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. ANESTHESIOLOGY 2007; 106:746-53
7. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31:347-54
8. Nakata Y, Goto T, Morita S: Comparison of inhalation inductions with xenon and sevoflurane. Acta Anaesthesiol Scand 1997; 41:1157-61
9. Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S: The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 1998; 80:255-6
10. Marion DW, Crosby K: The effect of stable xenon on ICP. J Cereb Blood Flow Metab 1991; 11:347-50
11. Schmidt M, Marx T, Armbruster S, Reinelt H, Schirmer U: Effect of Xenon on elevated intracranial pressure as compared with nitrous oxide and total intravenous anesthesia in pigs. Acta Anaesthesiol Scand 2005; 49:494-501
12. Wappler F, Rossaint R, Baumert J, Scholz J, Tonner PH, van Aken H, Berendes E, Klein J, Gommers D, Hammerle A, Franke A, Hofmann T, Schulte Esch J; Xenon Multicenter Study Research Group: Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. ANESTHESIOLOGY 2007; 106:463-71
13. Laitio RM, Kaisti KK, Låangsjö JW, Aalto S, Salmi E, Maksimow A, Aantaa R, Oikonen V, Sipilä H, Parkkola R, Scheinin H: Effects of xenon anesthesia on cerebral blood flow in humans: A positron emission tomography study. ANESTHESIOLOGY 2007; 106:1128-33
14. Carlson AP, Brown AM, Zager E, Uchino K, Marks MP, Robertson C, Sinson GP, Marmarou A, Yonas H: Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: A multicenter study. AJNR Am J Neuroradiol 2011; 32:1315-20
15. Dingley J, Tooley J, Porter H, Thoresen M: Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37:501-6
16. Luo Y, Ma D, Ieong E, Sanders RD, Yu B, Hossain M, Maze M: Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. ANESTHESIOLOGY 2008; 109: 782-9
17. Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP: The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. ANESTHESIOLOGY 2003; 99:876-81
18. David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH: Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 2003; 23:1168-73
19. Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D: Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience 2010; 165:874-81
20. Ma D, Yang H, Lynch J, Franks NP, Maze M, Grocott HP: Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. ANESTHESIOLOGY 2003; 98:690-8
21. Schmidt M, Marx T, Glöggl E, Reinelt H, Schirmer U: Xenon attenuates cerebral damage after ischemia in pigs. ANESTHESIOLOGY 2005; 102:929-36
22. Fries M, Coburn M, Nolte KW, Timper A, Kottmann K, Kuru TH, Weis J, Rossaint R: Early administration of xenon or isoflurane may not improve functional outcome and cerebral alterations in a porcine model of cardiac arrest. Resuscitation 2009; 80:584-90
23. Sakai H, Sheng H, Yates RB, Ishida K, Pearlstein RD, Warner DS: Isoflurane provides long-term protection against focal cerebral ischemia in the rat. ANESTHESIOLOGY 2007; 106:92-9; discussion 8-10
24. Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS: Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: A comparison with dizocilpine. Anesth Analg 2004; 99:896-903
25. Sheng H, Spasojevic I, Tse HM, Jung JY, Hong J, Zhang Z, Piganelli JD, Batinic-Haberle I, Warner DS: Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: Rodent models of ischemic stroke and subarachnoid hemorrhage. J Pharmacol Exp Ther 2011; 338:906-16
26. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10:290-3
27. Warner DS, Ludwig PS, Pearlstein R, Brinkhous AD: Halothane reduces focal ischemic injury in the rat when brain temperature is controlled. ANESTHESIOLOGY 1995; 82:1237-45; discussion 27A
28. Kollmar R, Blank T, Han JL, Georgiadis D, Schwab S: Different degrees of hypothermia after experimental stroke: Short-and long-term outcome. Stroke 2007; 38:1585-9
29. James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT: Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke 2009; 40:632-9
30. James ML, Wang H, Venkatraman T, Song P, Lascola CD, Laskowitz DT: Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. J Neurotrauma 2010; 27:217-28
31. Wang Z, Yang W, Britz GW, Lombard FW, Warner DS, Sheng H: Development of a simplified spinal cord ischemia model in mice. J Neurosci Methods 2010; 189:246-51
32. Sheng H, Reynolds JD, Auten RL, Demchenko IT, Piantadosi CA, Stamler JS, Warner DS: Pharmacologically augmented S-nitrosylated hemoglobin improves recovery from murine subarachnoid hemorrhage. Stroke 2011; 42:471-6
33. Wang J: Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol 2010; 92:463-77
34. Sansing LH, Harris TH, Welsh FA, Kasner SE, Hunter CA, Kariko K: Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage. Ann Neurol 2011; 70:646-56
35. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon produce anaesthesia? Nature 1998; 396:324
36. Morimoto Y, Wu B, Bart RD, Morimoto Y, Pearlstein RD, Warner DS: Effects of NMDA receptor glycine recognition site antagonism on cerebral metabolic rate for glucose and cerebral blood flow in the conscious rat. Brain Res 1998; 779:170-6
37. Dyker AG, Lees KR: Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke 1999; 30:986-92
38. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26:503-13
39. Takaoka S, Bart RD, Pearlstein R, Brinkhous A, Warner DS: Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J Cereb Blood Flow Metab 1997; 17:161-7
40. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; Glycine Antagonist in Neuroprotection Americas Investigators: Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. JAMA 2001; 285:1719-28
41. David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH: Neuroprotective effects of xenon: A therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 2008; 22:1275-86
42. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7
43. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U; SAINT II Trial Investigators: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357:562-71
44. Sheng H, Yang W, Fukuda S, Tse HM, Paschen W, Johnson K, Batinic-Haberle I, Crapo JD, Pearlstein RD, Piganelli J, Warner DS: Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat. Free Radic Biol Med 2009; 47:917-23
45. Colbourne F, Corbett D: Delayed and prolonged post-ischemic hypothermia is neuroprotective in the gerbil. Brain Res 1994; 654:265-72
46. Margaill I, Parmentier S, Callebert J, Allix M, Boulu RG, Plotkine M: Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J Cereb Blood Flow Metab 1996; 16:107-13
47. Berger C, Stauder A, Xia F, Sommer C, Schwab S: Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia. Exp Neurol 2008; 210:543-8
48. Martin JL, Ma D, Hossain M, Xu J, Sanders RD, Franks NP, Maze M: Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br J Anaesth 2007; 98:236-40
49. Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J: Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008; 39:1307-13
50. Thoresen M, Hobbs CE, Wood T, Chakkarapani E, Dingley J: Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab 2009; 29:707-14
51. Doufas AG, Lin CM, Suleman MI, Liem EB, Lenhardt R, Morioka N, Akça O, Shah YM, Bjorksten AR, Sessler DI: Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 2003; 34:1218-23
52. Bedi A, McCarroll C, Murray JM, Stevenson MA, Fee JP: The effects of subanaesthetic concentrations of xenon in volunteers. Anaesthesia 2002; 57:233-41
53. Bedi A, Murray JM, Dingley J, Stevenson MA, Fee JP: Use of xenon as a sedative for patients receiving critical care. Crit Care Med 2003; 31:2470-7
54. Schiltz M, Fourme R, Broutin I, Prangé T: The catalytic site of serine proteinases as a specific binding cavity for xenon. Structure 1995; 3:309-16
55. David HN, Haelewyn B, Risso JJ, Colloc'h N, Abraini JH: Xenon is an inhibitor of tissue-plasminogen activator: Adverse and beneficial effects in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2010; 30:718-28
56. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R: Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48:3307-12
57. Illanes S, Zhou W, Heiland S, Markus Z, Veltkamp R: Kinetics of hematoma expansion in murine warfarin-associated intracerebral hemorrhage. Brain Res 2010; 1320:135-42
58. Nakamura T, Kuroda Y, Hosomi N, Okabe N, Kawai N, Tamiya T, Xi G, Keep RF, Itano T: Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat. Acta Neurochir Suppl 2010; 106:307-10